Literature DB >> 22020632

Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex.

Stephen Arold1, Patrick Sullivan, Tina Bilousova, Edmond Teng, Carol A Miller, Wayne W Poon, Harry V Vinters, Lindsey B Cornwell, Tommy Saing, Gregory M Cole, Karen Hoppens Gylys.   

Abstract

The apolipoprotein E4 allele (APOE4) contributes to Alzheimer's disease (AD) risk and APOE2 is protective, but the relevant cellular mechanisms are unknown. We have used flow cytometry analysis to measure apolipoprotein E (apoE) and amyloid beta peptide (Aβ) levels in large populations of synaptic terminals from AD and aged cognitively normal controls, and demonstrate that modest but significant increases in soluble apoE levels accompany elevated Aβ in AD cortical synapses and in an APP/PS1 rat model of AD. Dual labeling experiments document co-localization of apoE and Aβ in individual synapses with concentration of Aβ in a small population of apoE-positive synapses in both AD and controls. Consistent with a clearance role, the apoE level was higher in Aβ-positive synapses in control cases. In aged targeted replacement mice expressing human apoE, apoE2/4 synaptic terminals demonstrated the highest level of apoE and the lowest level of Aβ compared to apoE3/3 and apoE4/4 lines. In apoE2/4 terminals, the pattern of immunolabeling for apoE and Aβ closely resembled the pattern in human control cases, and elevated apoE was accompanied by elevated free cholesterol in apoE2/4 synaptic terminals. These results are consistent with a role for APOE in Aβ clearance in AD synapses, and suggest that optimal lipidation of apoE2 compared to E3 and E4 makes an important contribution to Aβ clearance and synaptic function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020632      PMCID: PMC3404604          DOI: 10.1007/s00401-011-0892-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  77 in total

1.  Control of synapse number by glia.

Authors:  E M Ullian; S K Sapperstein; K S Christopherson; B A Barres
Journal:  Science       Date:  2001-01-26       Impact factor: 47.728

2.  Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

Authors:  Salvatore Oddo; Antonella Caccamo; Jason D Shepherd; M Paul Murphy; Todd E Golde; Rakez Kayed; Raju Metherate; Mark P Mattson; Yama Akbari; Frank M LaFerla
Journal:  Neuron       Date:  2003-07-31       Impact factor: 17.173

3.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.

Authors:  J Näslund; V Haroutunian; R Mohs; K L Davis; P Davies; P Greengard; J D Buxbaum
Journal:  JAMA       Date:  2000 Mar 22-29       Impact factor: 56.272

Review 4.  APOE and cholesterol homeostasis in Alzheimer's disease.

Authors:  Valérie Leduc; Stéphanie Jasmin-Bélanger; Judes Poirier
Journal:  Trends Mol Med       Date:  2010-10       Impact factor: 11.951

5.  ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.

Authors:  James J Donkin; Sophie Stukas; Veronica Hirsch-Reinshagen; Dhananjay Namjoshi; Anna Wilkinson; Sharon May; Jeniffer Chan; Jianjia Fan; Jon Collins; Cheryl L Wellington
Journal:  J Biol Chem       Date:  2010-08-25       Impact factor: 5.157

6.  Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals.

Authors:  Karen H Gylys; Jeffrey A Fein; Aiko M Tan; Gregory M Cole
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

7.  The effect of APOE genotype on brain levels of oxysterols in young and old human APOE epsilon2, epsilon3 and epsilon4 knock-in mice.

Authors:  A M Jenner; W L F Lim; M P E Ng; M R Wenk; G Shui; M J Sharman; S E Gandy; R N Martins
Journal:  Neuroscience       Date:  2010-04-21       Impact factor: 3.590

Review 8.  ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function.

Authors:  Arlene M Manelli; W Blaine Stine; Linda J Van Eldik; Mary Jo LaDu
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

9.  Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice.

Authors:  P M Sullivan; B E Mace; N Maeda; D E Schmechel
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

10.  Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients.

Authors:  Y Ji; Y Gong; W Gan; T Beach; D M Holtzman; T Wisniewski
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

View more
  25 in total

1.  Defective Transcytosis of APP and Lipoproteins in Human iPSC-Derived Neurons with Familial Alzheimer's Disease Mutations.

Authors:  Grace Woodruff; Sol M Reyna; Mariah Dunlap; Rik Van Der Kant; Julia A Callender; Jessica E Young; Elizabeth A Roberts; Lawrence S B Goldstein
Journal:  Cell Rep       Date:  2016-10-11       Impact factor: 9.423

2.  Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4.

Authors:  Tina Bilousova; Mikhail Melnik; Emily Miyoshi; Bianca L Gonzalez; Wayne W Poon; Harry V Vinters; Carol A Miller; Maria M Corrada; Claudia Kawas; Asa Hatami; Ricardo Albay; Charles Glabe; Karen H Gylys
Journal:  Am J Pathol       Date:  2019-05-17       Impact factor: 4.307

3.  Co-Expression of Glia Maturation Factor and Apolipoprotein E4 in Alzheimer's Disease Brain.

Authors:  Ramasamy Thangavel; Sachin M Bhagavan; Swathi Beladakere Ramaswamy; Spurthi Surpur; Raghav Govindarajan; Duraisamy Kempuraj; Smita Zaheer; Sudhanshu Raikwar; Mohammad E Ahmed; Govindhasamy Pushpavathi Selvakumar; Shankar S Iyer; Asgar Zaheer
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

4.  Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.

Authors:  Leon M Tai; Tina Bilousova; Lisa Jungbauer; Stephen K Roeske; Katherine L Youmans; Chunjiang Yu; Wayne W Poon; Lindsey B Cornwell; Carol A Miller; Harry V Vinters; Linda J Van Eldik; David W Fardo; Steve Estus; Guojun Bu; Karen Hoppens Gylys; Mary Jo Ladu
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

5.  Human APOE genotype affects intraneuronal Aβ1-42 accumulation in a lentiviral gene transfer model.

Authors:  Wenjuan Zhao; Sonya B Dumanis; Irfan Y Tamboli; Gustavo A Rodriguez; Mary Jo Ladu; Charbel E H Moussa; G William Rebeck
Journal:  Hum Mol Genet       Date:  2013-10-23       Impact factor: 6.150

6.  Variability in APOE genotype status in human-derived cell lines: a cause for concern in cell culture studies?

Authors:  Sebastian Schaffer; Vanessa Y M Lam; Insa M A Ernst; Patricia Huebbe; Gerald Rimbach; Barry Halliwell
Journal:  Genes Nutr       Date:  2013-12-03       Impact factor: 5.523

7.  Endogenous Apolipoprotein E (ApoE) Fragmentation Is Linked to Amyloid Pathology in Transgenic Mouse Models of Alzheimer's Disease.

Authors:  Anika Saul; Oliver Wirths
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

8.  Disentangling the effects of age and APOE on neuropathology and late life cognitive decline.

Authors:  Lei Yu; Patricia A Boyle; Sue Leurgans; Julie A Schneider; David A Bennett
Journal:  Neurobiol Aging       Date:  2013-10-09       Impact factor: 4.673

9.  Brain regional correlation of amyloid-β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-β accumulation.

Authors:  Mitsuru Shinohara; Ronald C Petersen; Dennis W Dickson; Guojun Bu
Journal:  Acta Neuropathol       Date:  2013-01-31       Impact factor: 17.088

10.  Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial.

Authors:  Angela J Hanson; Jennifer L Bayer-Carter; Pattie S Green; Thomas J Montine; Charles W Wilkinson; Laura D Baker; G Stennis Watson; Laura M Bonner; Maureen Callaghan; James B Leverenz; Elaine Tsai; Nadia Postupna; Jing Zhang; Johanna Lampe; Suzanne Craft
Journal:  JAMA Neurol       Date:  2013-08       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.